

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 07-1-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 29-9-2007 TO BE PUBLISHED ON 08-1-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1118/2007	<u>24-9-2007</u> Hubert Hereth, Switzerland (Priority 02-10-06 Germany)	“Funnel extraction II”
1119/2007	Schering Corporation, USA (Priority 26-9-06 USA)	“Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist”
1120/2007	Honda Motor Co. Ltd. Japan (Priority 24-11-06 Japan)	“Internal combustion engine including decompression system”
1121/2007	Novartis AG. Switzerland. (Priority 27-09-2006 EP)	“Pharmaceutical Compositions”
1122/2007	<u>25-09-2007</u> Sanofi-Aventis. France. (Priority 19-10-2006 EP)	“Novel anti-cd38 antibodies for the treatment of cancer”
1123/2007	Otsuka Pharmaceutical Co., Ltd. Japan. (Priority 02-10-2006 Japan)	“Stat 3/5 activation inhibitor”
1124/2007	Zakiuddin Ahmed. Karachi-Pakistan.	“A process for the production of nitro ammonium humate (named as coal nitrogen) for nitrogen deficient crops from Pakistan Coal”
1125/2007	Zakiuddin Ahmed. Karachi-Pakistan.	“A process for the production of calcium humate dye/pigment (named as red coal) using low grade Pakistan Coal”
1126/2007	GlaxoSmithKline Biologicals S.A. Belgium. (Priority 27-09-2006 GB)	“Novel Process”

1127/2007	Wyeth. USA. (Priority 26-09-2006 USA)	“Process for the preparation of 4-hydroxythieno [2,3-B] pyridine-5-carbonitriles”
1128/2007	AstraZeneca AB Sweden. (Priority 05-10-2006 USA)	“Mglur5 modulators”
1129/2007	KuDos Pharmaceuticals Limited. United Kingdom. (Priority 17-10-2006 USA)	“Phthalazinone Derivative”
1130/2007	Janssen Pharmaceutica N.V. Belgium (Priority 05-10-2006 USA)	“Heterocyclic derived metalloprotease inhibitors”
1131/2007	Janssen Pharmaceutica N.V. Belgium. (Priority 06-10-2006 USA)	“Matrix metalloprotease inhibitors”
	<u>26-09-2007</u>	
1132/2007	Bayer CropScience AG. Germany. (Priority 30-09-2006 EP)	“Improvement of the biological action of agrochemical compositions on application to the culture substrate. Suitable formulations and their use”
1133/2007	Bayer CropScience AG. Germany. (Priority 30-09-2006 EP)	“Suspension concentrates for improving root uptake of agrochemiscally active compounds”
1134/2007	DyStar Textilfarben GmbH & Co. Deutschland KG Germany. (Priority 29-09-2006 Germany)	“Colored organopolysiloxanes”
	<u>27-09-2007</u>	
1135/2007	Sicpa Holding S.A. Switzerland. (Priority 17-10-2006 EP)	“Method and means for magnetically transferring indicia to a coating composition applied on a substrate”
1136/2007	Leco Stationary Manufacturing Company Limited. Hong Kong. (Priority 31-10-2006 China)	“Lever arch mechanism”

1137/2007	SmithKline Beecham Corporation. USA. (Priority 29-09-2006 USA)	“Chemical Compounds”
1138/2007	Santoni S.p.A. Italy. (Priority 29-09-2006 Italy)	“Yarn feeding device for knitting machines, particularly for circular knitting machines”
1139/2007	Banyu Pharmaceutical Co. Ltd. Japan. (Priority 06-10-2006 Japan)	“2-Pyridinecarboxamide derivative having gk-activating effect”
1140/2007	N.V. Organon. The Netherlands. (Priority 27-09-2006 EP)	“New progesterone receptor modulators”
	<u>28-09-2007</u>	
1141/2007	Eisai R&D Management Co., Ltd. Japan. (Priority 12-05-2004 Japan) Divisional	“A pharmacologically acceptable salt of an indole-derived compound having piperidine ring for use as a pharmaceutical “
	<u>29-09-2007</u>	
1142/2007	Takeda Pharmaceutical Company Limited. Japan. (Priority 06-10-2006 Japan)	“Agent for preventing/treating cancer”
1143/2007	Momentive Performance Materials Inc. USA. (Priority 06-10-2006 USA)	“Mercaptofunctional silane process for its preparation”
1144/2007	Momentive Performance Materials Inc. USA. (Priority 06-10-2006 USA)	“Elastomer composition containing mercaptofunctional silane and process for making same”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


746/2002 AstraZeneca AB
Sweden

“Mandelic acid compound”

(CO7D, 205/04)

139313

There is provided a compound of formula I



Which compound is useful as, is competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is

required (e.g. thrombosis) or as anticoagulants.

223/2005 LES Laboratoires Servier
France


“New γ crystalline form of perindopril tert-butylamine salt, a process for its preparation ”

(CO7D, 209/42)

139314

NEW γ CRYSTALLINE FORM OF PERINDOPRIL
TERT-BUTYLAMINE SALT,
A PROCESS FOR ITS PREPARATION

γ crystalline form of the compound of formula (I)



Characterised by its powder X-ray diffraction diagram.

276/2005 Recon Oil Industries
Private Limited
India

“A synergistically heat stable oil media having eicosa
pentaenoic acid (EPA) and docosa hexaenoic acid
(DHA)”

(C11C, 3/08)

139315

A synergistically heat stable therapeutically active triglyceride and cholesterol controlling oil composition including the usually highly unsaturated Eicosa Pentaenoic Acid (ERA) and Docosa Hexaenoic Acid (DHA). The invention avoids limitations of presently available impure sources of ERA / DHA such as fish oil, algae and the like and provides for a synergistically stable edible oil formulation involving the Eicosa Pentaenoic Acid and Docosa Hexaenoic acid of at least 35% to less than 100% purity in a free of any encapsulated / protected form in combination with synergistically stability contributing oil constituents / ingredients. The invention also provides for benefit applications / uses of the surprising and unexpected heat stability of the beneficial actives ERA and DHA. The invention is therefore directed to serve in possible provision of variety of alternative media including heat stable media for regular consumption of ERA / DHA and provide for maintenance of safe and healthy lifestyle.

XXXXXXXXXXXXXXXX